Insider · CIK 0001699200
Brian Bonner
Files at DSKE (Daseke, Inc.), ONEN (ONE Nuclear Energy Inc.). First filing -, latest -.
In brief
Brian Bonner files SEC Form 4 as director at DSKE (Daseke, Inc.), and also at ONEN (ONE Nuclear Energy Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Brian Bonner has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 23, 2026 | ONEN ONE Nuclear Energy Inc. | MOption exercise Class A ordinary shares | +25,000 | - | - | 25,000 | 20 d ago |
| Sep 23, 2026 | ONEN ONE Nuclear Energy Inc. | MOption exercise Class B ordinary sharesderivative | -25,000 | $0.00 | $0 | 0 | 20 d ago |
| Jan 1, 2024 | DSKE Daseke, Inc. | MOption exercise Common Stock | +19,332 | $0.00 | $0 | 514,131 | Jan 3, 2024 |
| Jan 1, 2024 | DSKE Daseke, Inc. | MOption exercise Restricted Stock Unitderivative | -19,332 | $0.00 | $0 | 0 | Jan 3, 2024 |
Questions about Brian Bonner
Answered from the filings on this page, as of the latest one.
Is Brian Bonner buying or selling?
Brian Bonner has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Brian Bonner's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Brian Bonner has 0.
Where does Brian Bonner file Form 4?
Brian Bonner has filed Form 4 at DSKE (Daseke, Inc.); ONEN (ONE Nuclear Energy Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.